Literature DB >> 10072247

Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women.

K K Koh1, M K Horne, G Csako, M A Waclawiw, R O Cannon.   

Abstract

To determine whether enhanced fibrinolysis is a primary effect of estrogen or is secondary to activation of coagulation, we measured hemostatic factors before and after conjugated equine estrogen 0.625 mg/day for 1 month in 9 postmenopausal women. We found that potentiation of fibrinolysis is a primary effect of conjugated equine estrogens at this commonly used dosage in healthy postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072247     DOI: 10.1016/s0002-9149(98)00891-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

Review 1.  Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women.

Authors:  Kwang Kon Koh
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy.

Authors:  Daniela Amorim Melgaço Guimarães; Maria das Graças Carvalho; Jarbas Cardoso; Marinez de Oliveira Sousa; Romerson Martins Franco; Hilton de Almeida Franco; Túlio César Alvim; George da Silva Teixeira; Luci Maria SantAna Dusse; Ana Paula Fernandes
Journal:  J Thromb Thrombolysis       Date:  2007-12-04       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.